CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
MP-214 3mg +2 moredrug
Likely dose
MP-214 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01626859
NCT01626859Phase 3Completed
CompareCT.gov

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)

Tanabe Pharma Corporation·interventional·Posted Jun 25, 2012·Updated Jan 5, 2026

In Brief

A Phase 3 clinical trial evaluating MP-214 3mg, MP-214 6mg, and 1 other intervention for Schizophrenia. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2012
Enrollment StartMay 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.0 years ago

Interventions

MP-214 3mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.

MP-214 6mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.

MP-214 9mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.